Condition: Autism Spectrum Disorder · Challenging Behaviour · Aggression · Sponsor: Jeremy Veenstra-vanderweele
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.
This description comes directly from the study's public registry record.
Suvekcha Bhattachan, MA · 914-997-5587 · suvekcha.bhattachan@nyspi.columbia.edu
Alyssa Verdes, BA · 914-997-5532 · alyssa.verdes@nyspi.columbia.edu
Always discuss trial participation with your own doctor first.
| New York State Institute for Basic Research (IBR) | Staten Island, New York, United States | Recruiting |
| Center for Autism and the Developing Brain | White Plains, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07091279